Zinc acetate

Overview

No overview information available.

Background

No background information available.

Indication

Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections .

Associated Conditions

Pruritus
Skin Irritation
Oozing and weeping
Pain and itching

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Prospective Pilot Trial to Address Feasibility and Safety of Oral Zinc in GNAO1 Associated Disorders	2024/05/14	NCT06412653	Phase 2	Not yet recruiting	Children's University Hospital Cologne, Germany
Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers	2016/08/16	NCT02868151	Phase 2	Completed	Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency	2015/01/13	NCT02337569	Phase 3	Completed	Nobelpharma
Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency	2014/12/22	NCT02321865	Phase 3	Completed	Nobelpharma
The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy	2008/06/12	NCT00696410	Phase 1	Completed	University of Michigan
The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children	2006/09/07	NCT00373100	Phase 3	Completed	Makerere University
Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.	2005/09/21	NCT00212355	Phase 3	Completed	Nobelpharma
Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan.	2005/09/21	NCT00212368	Phase 3	Completed	Nobelpharma
Study of Zinc for Wilson Disease	1999/10/19	NCT00004338	Phase 4	Completed	National Center for Research Resources (NCRR)

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Itch Relief	The Kroger Co	59450-295	TOPICAL	1 mg in 1 mL	3/31/2025
foster and thrive anti itch cream	Strategic Sourcing Services LLC	70677-1289	TOPICAL	0.1 g in 100 g	4/30/2025
GALZIN	Teva Pharmaceuticals USA, Inc.	57844-208	ORAL	50 mg in 1 1	8/16/2023
GALZIN	Teva Pharmaceuticals USA, Inc.	57844-215	ORAL	25 mg in 1 1	8/16/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
NUTRIFLEX® OMEGA SPECIAL EMULSION FOR INFUSION	B. Braun Melsungen AG	SIN15469P	INJECTION, EMULSION	7.024mg/1000ml	4/23/2018
NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION	B. Braun Melsungen AG	SIN15468P	INJECTION, EMULSION	5.264mg/1000ml	4/23/2018
NUTRIFLEX® OMEGA SPECIAL B. BRAUN EMULSION FOR INFUSION	B. Braun Melsungen AG	SIN16734P	INJECTION, EMULSION	7.024mg/1000ml	3/7/2023

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
Zinc Acetate Tablets	NOBELPHARMA CO., LTD.	国药准字HJ20240007	化学药品	片剂	2/6/2024
Zinc Acetate Tablets	NOBELPHARMA CO., LTD.	国药准字HJ20240006	化学药品	片剂	2/6/2024

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Eton Pharmaceuticals Poised for Growth with Expanding Rare Disease Portfolio and Pending FDA Approvals

4 months ago

Eton Pharmaceuticals is anticipating FDA approval for ET-400 in early June, with commercial launch planned immediately following approval and significant revenue impact expected in Q3 and Q4 2025.

Eton Pharmaceuticals Launches FDA-Approved Galzin for Wilson Disease Maintenance Treatment